Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial ProductGlobeNewsWire • 08/31/23
Can Zevra Therapeutics (ZVRA) Climb 227.55% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/17/23
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/14/23
Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. PloosterGlobeNewsWire • 08/07/23
Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical ConferenceGlobeNewsWire • 07/19/23
Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023GlobeNewsWire • 06/20/23
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-VestGlobeNewsWire • 06/13/23
Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023GlobeNewsWire • 06/03/23
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/15/23
Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial ResultsGlobeNewsWire • 05/15/23
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023GlobeNewsWire • 05/10/23
Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in NarcolepsyGlobeNewsWire • 05/03/23
Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra's Transformation StrategyGlobeNewsWire • 04/17/23
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of DirectorsGlobeNewsWire • 03/30/23
Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data InitiativeGlobeNewsWire • 03/17/23
Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to ShareholdersGlobeNewsWire • 03/15/23
Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 03/07/23